6196775
Last Update Posted: 2024-01-09
Recruiting has not begun
All Genders accepted | 18 Years-75 Years |
36 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of cadonilimab combined with AK112 as second-line therapy in patients with advanced hepatocellular carcinoma.
Eligibility
Relevant conditions:
Hepatocellular Carcinoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Yanqiao Zhang, PhD.
yanqiaozhang@126.com
13845120210
Guangyu Wang, PhD.
guangyuwang@hrbmu.edu.cn
18249038966
Data sourced from ClinicalTrials.gov